MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife (MET) reported an insider administrative transaction by its EVP & Chief Legal Officer. On 10/31/2025, 4,420 shares of common stock were withheld at $79.82 under transaction code F, which indicates shares withheld to cover taxes on restricted stock units.
After this transaction, the reporting person directly owned 10,452 shares.
MetLife, Inc. (MET) disclosed an insider equity transaction by its EVP & Chief Accounting Officer. On 10/31/2025, the officer acquired 11,902 shares of common stock, reported as directly owned after the transaction. A footnote indicates these shares relate to restricted stock units, each representing the right to receive one share of MetLife common stock.
This filing records an equity award event and updates the officer’s reported holdings; it does not reflect an open‑market purchase or sale.
The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting beneficial ownership of 64,749,341 MetLife (MET) common shares, representing 9.73% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 3,353,980 with shared voting power. It has sole dispositive power over 59,193,894 shares and shared dispositive power over 5,555,447 shares. The filing identifies Vanguard as an investment adviser and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds related to the reported securities, and that no single other person’s interest exceeds 5%.
Rule 144 notice: A holder filed to sell 196 shares of common stock through Barclays on the NYSE. The filing lists an aggregate market value of $15,435 and an approximate sale date of 10/29/2025. Shares outstanding were 665,026,054.
The filer reports prior sales in the past three months by related accounts, including 333 shares on 10/01/2025 for gross proceeds of $27,282.69. This notice reflects a proposed secondary sale by an existing holder.
MetLife, Inc. filed a Certificate of Elimination to remove its 3.850% Fixed Rate Reset Non‑Cumulative Preferred Stock, Series G, from its charter effective upon filing. The company previously redeemed, repurchased or otherwise reacquired all Series G shares.
The filing eliminates the Series G Certificate of Designations from the Amended and Restated Certificate of Incorporation. Shares formerly designated as Series G return to authorized but unissued preferred stock, par value $0.01 per share, without designation as to series.
MetLife, Inc. (MET) non‑management director Carla A. Harris acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After this transaction the reporting person beneficially owned 9,048 shares. The filing states these shares represent part of director retainer fees that were elected to be deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 10/03/2025.
Laura J. Hay, a non‑management director of MetLife, Inc. (MET), reported a purchase of 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction, the reporting person beneficially owned 4,261 shares. The Form 4 notes these shares are part of the director retainer that the director elected to defer under the MetLife Deferred Compensation Plan for Non‑Management Directors. The filing was signed by an attorney‑in‑fact on 10/03/2025. The form contains no options or derivative transactions and no other changes to ownership were disclosed.
MetLife, Inc. director Diana McKenzie acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share under the company’s non‑management director compensation program. The filing states that a portion of non‑management director retainer fees are paid in common stock and that Ms. McKenzie elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non‑Management Directors. After this transaction she beneficially owns 22,757 shares, reported as direct ownership. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The disclosure is limited to the director grant and deferral; no additional financial results, guidance, or other transactions are included in this filing.
MetLife, Inc. (MET) non-management director Christian Stephane Mumenthaler reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction he beneficially owned 1,458 shares. The filing states these shares were part of director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The report reflects a routine compensation-related equity grant and deferral by a board member.
The Form 4 shows that Mark A. Weinberger, a non‑management director of MetLife, Inc. (MET), received 534 shares of MetLife common stock as part of the company's director compensation plan on 10/01/2025. After this award, his beneficial ownership totaled 17,441 shares. The filing states these shares were issued under MetLife's practice of paying a portion of non‑management director retainer fees in common stock.